JTC Employer Solutions Trustee Ltd lessened its position in GSK plc (NYSE:GSK - Free Report) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,278,564 shares of the pharmaceutical company's stock after selling 202,398 shares during the quarter. GSK comprises 48.3% of JTC Employer Solutions Trustee Ltd's holdings, making the stock its largest position. JTC Employer Solutions Trustee Ltd owned 0.98% of GSK worth $682,272,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Sunbelt Securities Inc. increased its holdings in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in GSK by 9.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company's stock worth $137,000 after purchasing an additional 303 shares during the period. Mesirow Financial Investment Management Inc. raised its position in GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock valued at $682,000 after purchasing an additional 323 shares during the period. Rehmann Capital Advisory Group raised its holdings in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock valued at $232,000 after buying an additional 332 shares during the period. Finally, Investment Partners Asset Management Inc. lifted its position in GSK by 2.3% in the third quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company's stock valued at $636,000 after buying an additional 344 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.
GSK Stock Down 1.1 %
NYSE:GSK traded down $0.38 during mid-day trading on Monday, hitting $32.71. The stock had a trading volume of 4,673,691 shares, compared to its average volume of 3,213,207. GSK plc has a twelve month low of $32.55 and a twelve month high of $45.92. The stock has a 50-day simple moving average of $34.38 and a two-hundred day simple moving average of $38.17. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $67.79 billion, a PE ratio of 21.24, a PEG ratio of 1.52 and a beta of 0.63.
GSK Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.80%. This is a positive change from GSK's previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. GSK's dividend payout ratio (DPR) is presently 95.45%.
Wall Street Analysts Forecast Growth
GSK has been the topic of a number of research analyst reports. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and reduced their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Monday. Finally, Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, GSK has an average rating of "Moderate Buy" and a consensus target price of $43.25.
Read Our Latest Analysis on GSK
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
